Glaxo Group Limited

Allen Hanburys Limited

Glaxco Group Limited

Allen & Hansbury, Limited

John Bradshaw

John W Clitherow

Barry J Price

Michael Martin-Smith

Duncan B Judd

Roger Hayes

John W MacKinnon

Ian H Coates

Eric W Collington

Christopher J Wallis

William L Mitchell

Peter Hallett

Linda Carey

Alexander W Oxford

David E Bays

David C Humber

Malcolm Clive Carter

George B Ewan

James A Bell

Norman F Hayes

John W Mackinnon

Michael D Dowle

Ian B Campbell

David I Scopes

Philip Blatcher

Ian Collins

Alan Wadsworth

William D Ollis

Andrew Pearce

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a hydrogen atom or a halogen atom or a group selected from C.sub.1-6 alkyl and C.sub.1-6 alkoxy;

Benzanilide derivatives

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a hydrogen atom, a halogen atom or a group selected from C.sub.1-6 alkyl and C.sub.1-6 alkoxy;

The invention provides compounds of formula (I): ##STR1## or a physiologically acceptable salt or solvate thereof wherein R.sup.1 represents a halogen or hydrogen atom or a C.sub.1-6 alkyl or C.sub.1-6 alkoxy group;

The invention relates to compounds of the general formula (I): ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 ;

Tricyclic ketones useful as HT.sub.3 -receptor antagonists

The invention relates to tetracyclic ketones of the general formula (I) ##STR1## wherein n represents 1, 2 or 3;

[(Imidazol-4(and 5)-yl)methyl] tetracyclic ketones having 5-HT.sub.3

The invention relates to compounds of the general formula (I): ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## and the various substituents are defined hereinbelow. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating

Tetrahydro carbazolone intermediates

The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and hydrates thereof, in which one of R.sub.1 and R.sub.2 represents hydrogen, halogen or a C.sub.1-4 alkyl group which may be optionally substituted by hydroxy or C.sub.1-4 alkoxy, and the other represents the group R.sub.4 R.sub.5 NAlk-- in which Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;

Heterocyclic derivatives, processes for the use thereof and

The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the variables are as defined in the specification. The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists. Also disclosed are intermediates in the preparation of the compounds of the formula (I).

3-[3-[1-piperidinylmethyl]phenoxy]propanamine

The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined in the detailed description. The compounds show pharmaceutical activity as selective histamine H.sub.2 -antagonists.

Triazole amine compounds, their pharmaceutical compositions and method

The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, which show pharmacological activity as selective histamine H.sub.2 -antagonists.

Triazoleamine derivatives having histamine H.sub.2 -antagonist properties

Compounds are described of the formulae (1a) and (1b) ##STR1## in which: --COR.sup.1 is an ester group,

Aminocyclopentane esters and pharmaceutical formulations

Compounds of the formula (I) ##STR1## in which R.sub.1 and R.sub.2 each may represent hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, or alkyl, substituted by hydroxy, C.sub.1-3 alkoxy, amino, C.sub.1-3 alkylamino or di-C.sub.1-3 alkylamino or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form an alicyclic heterocyclic ring which may be unsubstituted or may be substituted by one or more C.sub.1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom are described.

Pyrimidone derivatives

Compounds are described of the formula ##STR1## in which --COR.sup.1 is a complex ester or thioester group,

Aminocyclopentane esters and pharmaceutical formulation

The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, hydrates and bioprecursors thereof, in which the substituents are defined later. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

Growing community of inventors

Ware, United Kingdom

John Bradshaw